Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Immunotherapeutic Approaches for Endometrial Cancer

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

Program Schedule — Central Time

5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Sarah Karpen

Faculty

Sarah Karpen

MPAS, PA-C

Moores Cancer Center, University of California San Diego Health, San Diego, California

APP Supervisor Medical Oncology, Division of Gynecologic Oncology

J Alejandro Rauh-Hain

Faculty

J Alejandro Rauh-Hain

MD, MPH

The University of Texas MD Anderson Cancer Center Houston, Texas

Associate Professor, Tenure Track Deputy Division Head for Clinical Research, Division of Surgery Dept of Gynecologic Oncology and Reproductive Medicine Dept of Health Services Research

Jaclyn Shaver

Faculty

Jaclyn Shaver

MS, APRN, CNP, WHNP

OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology, Stephenson Cancer Center

Dana M Chase

Moderator

Dana M Chase

MD

David Geffen School of Medicine at UCLA, Los Angeles, California

Professor, Division of Gynecologic Oncology

Meeting space has been assigned to provide a symposium supported by GSK and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

    Program Schedule — Central Time

    5:30 PM – 6:00 PM — Registration and Dinner
    6:00 PM – 7:30 PM — Educational Meeting

    MODULE 1: Biology of Endometrial Cancer (EC); Rationale for the Use of Immune Checkpoint Inhibitors

    • Historical role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
    • Similarities and differences among the currently available anti-PD-1/PD-L1 antibodies for EC, such as dostarlimab, pembrolizumab and durvalumab
    • Biological rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
    • Frequency of potential biomarkers of response to immune checkpoint inhibitors in EC (eg, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, POLE mutations); optimal approach to biomarker assessment for patients with newly diagnosed disease

    MODULE 2: First-Line Therapy for Advanced or Recurrent EC

    • Key efficacy findings with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
    • Impact of MSI/MMR status on outcomes with the addition of anti-PD-1/PD-L1 antibodies to chemotherapy
    • FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MSI/MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease
    • Optimal incorporation of anti-PD-1/PD-L1 antibodies into up-front therapy for patients with advanced or recurrent EC

    MODULE 3: Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

    • Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors
    • Benefits observed with first-line dostarlimab and carboplatin/paclitaxel followed by dostarlimab/niraparib maintenance compared to carboplatin/paclitaxel alone in advanced or recurrent EC
    • Published efficacy and safety results with durvalumab in combination with chemotherapy followed by durvalumab and olaparib maintenance for patients with newly diagnosed advanced or recurrent EC
    • Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC

    MODULE 4: Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies for Previously Untreated Advanced EC

    • Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies in advanced EC
    • Recommended monitoring and management approaches for immune-related and other AEs with immune checkpoint inhibitors
    • Strategies to discern whether toxicities stem from anti-PD-1/PD-L1 antibodies or their therapeutic partners (eg, chemotherapy, PARP inhibitors) when these agents are administered in combination
    • Role of rechallenge in treatment for patients for whom immune checkpoint inhibitor therapy has been held due to immune-mediated toxicity
    • Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, in treatment for patients with preexisting autoimmune conditions or a history of solid organ transplant

    MODULE 5: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

    • Biological rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
    • Long-term findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with MMR-proficient advanced EC with disease progression after prior systemic therapy
    • Optimal integration of lenvatinib/pembrolizumab into EC management algorithms
    • Utility of lenvatinib/pembrolizumab among patients who have experienced disease progression on up-front chemoimmunotherapy

    MODULE 6: Toxicities with Lenvatinib/Pembrolizumab

    • Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab (eg, hypertension, gastrointestinal issues, weight loss, hand-foot syndrome)
    • Approaches to encourage adequate nutrition among patients receiving the combination of lenvatinib and pembrolizumab
    • Initial dosing and dose-modification strategies for lenvatinib/pembrolizumab in EC; available data exploring the impact of lenvatinib dose reductions on antitumor activity
    • Strategies to determine the cause of toxicities that could stem from either lenvatinib or pembrolizumab among patients receiving the combination

    Target Audience
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

    Learning Objectives
    Upon completion of this activity, participants should be able to

    • Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer (EC).
    • Appreciate available clinical research findings with the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
    • Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and reflect upon the potential role of this novel strategy.
    • Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
    • Appreciate the side effects associated with various systemic therapies commonly employed in the treatment of EC, and use this information to develop supportive management plans for patients undergoing treatment with these agents/regimens.
    • Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

    Accreditation Statement
    Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    Credit Designation Statements
    This educational activity for 1.5 contact hours is provided by Research To Practice.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/EndometrialCancer/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Credit Form
    To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

    Privacy Policy
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Unlabeled/Unapproved Uses Notice
    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Content Validation and Disclosures
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Ms Shaver and Dr Rauh-Hain have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

    Ms Karpen — Speakers Bureaus: Amgen Inc.

    MODERATOR — Dr Chase — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Merck; Consulting Agreements: AbbVie Inc, GSK; Contracted Research: GSK, Merck; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Pfizer Inc; Nonrelevant Financial Relationships: NRG Oncology.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
    Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    Supporters
    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

    Location
    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, TX 78205
    Hotel Phone: (210) 223-1000

    Meeting Room
    Grand Ballroom A-F (Third Floor)

    Directions
    The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

     

    Registration is now closed.

    Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Ovarian Cancer

    A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

    Program Schedule — Central Time

    5:30 PM – 6:00 PM — Registration and Dinner
    6:00 PM – 7:30 PM — Educational Meeting

    Location

    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, Texas
    Hotel Phone: (210) 223-1000

    Meeting Room

    Grand Ballroom A-F (Third Floor)

    No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

    Faculty

    Bradley J Monk

    Faculty

    Bradley J Monk

    MD

    Florida Cancer Specialists & Research Institute, West Palm Beach, Florida

    Medical Director, Late-Phase Research Program

    University of Central Florida College of Medicine

    Professor

    GOG Foundation, West Palm Beach, Florida

    Vice President and Member, Board of Directors

    GOG Partners, West Palm Beach, Florida

    Co-Director

    Faculty

    Kathryn M Schlenker

    MSN, WHNP-BC, AGNP-C

    The University of Alabama at Birmingham, Birmingham, Alabama

    Nurse Practitioner, Division of Gynecologic Oncology

    Jaclyn Shaver

    Faculty

    Jaclyn Shaver

    MS, APRN, CNP, WHNP

    OU Health, Oklahoma City, Oklahoma

    Section of Gynecologic Oncology, Stephenson Cancer Center

    David M O'Malley

    Moderator

    David M O'Malley

    MD

    The Ohio State University and The James Comprehensive Cancer Center, Columbus, Ohio

    Director and Professor, Division of Gynecologic Oncology in Obstetrics and Gynecology, John G Boutselis Chair in Gynecologic Oncology

    Meeting space has been assigned to provide a symposium supported by AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

      Program Schedule — Central Time

      5:30 PM – 6:00 PM — Registration and Dinner
      6:00 PM – 7:30 PM — Educational Meeting

      MODULE 1: Importance of Genetic Testing in the Care of Patients with Newly Diagnosed Advanced Ovarian Cancer (OC)

      • Similarities and differences between germline and somatic genetic mutations
      • Incidence and clinical significance of BRCA mutations and other germline or somatic alterations (eg, PALB2, ATM, RAD51C/D) in ovarian cancer
      • Current roles of next-generation sequencing and germline sequencing for advanced ovarian cancer; similarities and differences among available genetic testing platforms
      • Purpose and potential benefits of genetic counseling after a diagnosis of ovarian cancer

      MODULE 2: Role of PARP Inhibitors for Advanced Ovarian Cancer

      • Mechanism of antitumor activity of PARP inhibitors, and rationale for their use as maintenance therapy for patients with newly diagnosed advanced ovarian cancer
      • Long-term findings from Phase III studies with olaparib, olaparib/bevacizumab and niraparib maintenance for newly diagnosed ovarian cancer
      • Clinical, biological and practical factors affecting the selection of up-front olaparib, olaparib/bevacizumab or niraparib maintenance
      • Current clinical utility, if any, of PARP inhibitors for relapsed/refractory ovarian cancer, including among patients who have experienced disease progression on or after prior PARP inhibitor therapy

      MODULE 3: Side Effects and Other Practical Considerations with PARP Inhibitors

      • Initial dosing and appropriate dose-modification strategies for approved PARP inhibitors
      • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with ovarian cancer
      • Optimal monitoring and management paradigms for common PARP inhibitor-related toxicities
      • Long-term risk of acute myeloid leukemia/myelodysplastic syndromes with PARP inhibitor therapy
      • Importance of adherence among patients receiving long-term oral medications, including PARP inhibitors; strategies to encourage and assess adherence

      MODULE 4: Current and Future Role of Mirvetuximab Soravtansine in Ovarian Cancer Treatment

      • Frequency of and scientific rationale for targeting folate receptor alpha (FRα) in ovarian cancer
      • Mechanism of action and structural components of mirvetuximab soravtansine
      • Published research findings with mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer
      • FDA approval of mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer; implications for biomarker assessment and current management
      • Early findings with mirvetuximab soravtansine for FRα-high, platinum-sensitive advanced ovarian cancer; ongoing evaluation and potential utility in this setting

      MODULE 5: Toxicities Associated with Mirvetuximab Soravtansine

      • Pathophysiology and incidence of ocular toxicities observed with mirvetuximab soravtansine
      • Monitoring and management techniques for mirvetuximab soravtansine-related ocular events
      • Importance of collaboration with eye care specialists for patients receiving mirvetuximab soravtansine
      • Spectrum, frequency, severity and timing of other common toxicities reported with mirvetuximab soravtansine; optimal management approaches

      MODULE 6: Other Approved and Investigational Antibody-Drug Conjugates for Ovarian Cancer

      • Frequency of HER2 expression in advanced ovarian cancer; optimal timing of and approach to testing
      • FDA approval of trastuzumab deruxtecan for pretreated HER2-positive solid tumors; implications for ovarian cancer management
      • Biological rationale for targeting CDH6 for ovarian cancer; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
      • Early research findings with and ongoing evaluation of R-DXd for heavily pretreated platinum-resistant advanced ovarian cancer

      MODULE 7: Current Role of Relacorilant for Advanced OC

      • Incidence and clinical relevance of glucocorticoid receptor (GR) overexpression in ovarian cancer
      • Mechanism of action of the selective GR modulator relacorilant; rationale for combining relacorilant with chemotherapy for advanced ovarian cancer
      • Published efficacy and safety findings with relacorilant in combination with nab paclitaxel versus nab paclitaxel alone for platinum-resistant advanced ovarian cancer
      • Recent FDA approval of relacorilant in combination with nab paclitaxel for platinum-resistant advanced ovarian cancer, and integration into current clinical algorithms

      MODULE 8: Tolerability Considerations with Relacorilant/Nab Paclitaxel

      • Rationale for nab paclitaxel as a therapeutic partner for relacorilant; necessity of avoiding corticosteroid use with relacorilant
      • Tolerability profile of relacorilant/nab paclitaxel in published clinical trials; relative contributions of each agent in terms of toxicities
      • Incidence and severity of cytopenias with relacorilant/nab paclitaxel; appropriate monitoring and management
      • Rates of and strategies to manage peripheral neuropathy with relacorilant/nab paclitaxel

      MODULE 9: Utility of Immune Checkpoint Inhibition for Advanced OC

      • Historical outcomes documented with anti-PD-1/PD-L1 antibodies as monotherapy for advanced ovarian cancer; potential explanations for the lack of activity with these agents for ovarian cancer relative to other tumor types
      • Emerging data demonstrating a progression-free survival advantage with the addition of pembrolizumab to chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer
      • Impact of PD-L1 expression on overall survival in the aforementioned emerging data set; potential implications for biomarker analysis for advanced ovarian cancer
      • Potential clinical role of pembrolizumab for platinum-resistant recurrent ovarian cancer

      Target Audience
      This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

      Learning Objectives
      Upon completion of this activity, participants should be able to

      • Understand available clinical research findings with PARP inhibitors alone or in combination with bevacizumab as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and counsel appropriate individuals regarding personalized treatment recommendations.
      • Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
      • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
      • Understand the structural components and mechanism of action of antibody-drug conjugates (ADCs) directed at folate receptor alpha, and discuss current research findings with these agents.
      • Assess available clinical research findings with immunotherapy in combination with chemotherapy for patients with platinum-resistant OC, and consider the integration of this therapeutic strategy into care for individuals with advanced disease.
      • Review Phase III findings with selective glucocorticoid receptor modulators with chemotherapy for patients with platinum-resistant OC, and consider the current role of this combination in this treatment setting.
      • Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.
      • Recall the biological rationale for the evaluation of other ADCs with alternative targets (eg, HER2, CDH6, TROP2) for OC, and consider the current and future role of these agents.

      Accreditation Statement
      Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

      Credit Designation Statements
      This educational activity for 1.5 contact hours is provided by Research To Practice.

      This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

      Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
      The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OvarianCancer/ILNA.

      ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

      Credit Form
      To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

      Privacy Policy
      Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

      Unlabeled/Unapproved Uses Notice
      There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

      Content Validation and Disclosures
      Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

      FACULTY — Ms Schlenker and Ms Shaver have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

      Dr Monk — Consulting Agreements: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

      MODERATOR — Dr O’Malley — Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics.

      RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
      Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

      Supporters
      This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

      Location
      San Antonio Marriott Rivercenter
      101 Bowie St
      San Antonio, TX 78205
      Hotel Phone: (210) 223-1000

      Meeting Room
      Grand Ballroom A-F (Third Floor)

      Directions
      The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

       

      Registration is now closed.

      Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates

      A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

      Program Schedule — Central Time

      10:45 AM – 11:15 AM — Registration and Lunch
      11:15 AM – 12:45 PM — Educational Meeting

      Location

      San Antonio Marriott Rivercenter
      101 Bowie St
      San Antonio, Texas
      Hotel Phone: (210) 223-1000

      Meeting Room

      Grand Ballroom A-F (Third Floor)

      No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

      Faculty

      Courtney Arn

      Faculty

      Courtney Arn

      CNP

      The Ohio State University, Columbus, Ohio

      The James Cancer Hospital and Solove Research Institute

      Jamie Carroll

      Faculty

      Jamie Carroll

      APRN, MSN, CNP

      Mayo Clinic, Rochester, Minnesota

      Assistant Professor, Oncology

      Edward B Garon

      Faculty

      Edward B Garon

      MD, MS

      David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, California

      Professor, Director, Thoracic Oncology Program, Director, Signal Transduction and Therapeutics Research Program

      Heather McArthur

      Faculty

      Heather McArthur

      MD, MPH, FASCO

      UT Southwestern Medical Center, Dallas, Texas

      Professor, Department of Internal Medicine, Clinical Director, Breast Cancer Program, Komen Distinguished Chair in Clinical Breast Cancer Research

      Kathleen N Moore

      Moderator

      Kathleen N Moore

      MD, MS

      Fred and Pamela Buffett Cancer Center at the University of Nebraska, Omaha, Nebraska

      Deputy Director and Director, Phase 1 Clinical Trials

      Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

        Program Schedule — Central Time

        10:45 AM – 11:15 PM — Registration and Lunch
        11:15 AM – 12:45 PM — Educational Meeting

        MODULE 1: Rationale for the Use of Antibody-Drug Conjugates (ADCs) as Cancer Treatment

        • Rationale for conjugating monoclonal antibodies with cytotoxic drugs to form ADCs; theoretical improvement of chemotherapy efficacy while reducing systemic exposure and toxicity
        • Structural components, such as antibodies, linkers and cytotoxic payloads, of commercially available and investigational ADCs
        • Direct mechanism of antitumor activity of ADCs and other means by which they can elicit an antitumor effect, such as bystander killing

        MODULE 2: Current and Future Role of ADCs in Cancer Therapy

        • FDA-approved indications for ADCs in various tumor types
        • Clinical significance of FDA breakthrough therapy designation and current ADCs in development receiving this distinction
        • Biological rationale for combining ADCs with other cancer therapies (eg, immune checkpoint inhibitors) and current and future role of this strategy in treatment
        • Emerging findings with and ongoing studies evaluating ADCs for patients with non-metastatic disease
        • Other promising investigational ADCs in clinical development

        MODULE 3: Practical Considerations with ADCs

        • Setting patient expectations regarding ADC efficacy and tolerability
        • Optimal timing for initiation of approved ADCs or consideration of a clinical trial evaluating 1 of these agents
        • ADC effectiveness for patients with CNS metastases
        • Mechanisms of resistance to ADCs; feasibility of using multiple agents in this class sequentially for the same patient

        MODULE 4: Cytopenias Associated with ADCs

        • Educating patients regarding the capacity of ADCs to cause acute “chemotherapy-like” side effects
        • Incidence and severity of neutropenia, thrombocytopenia and anemia with approved and investigational ADCs
        • Indications for prophylactic growth factor use for patients who are about to start treatment with an ADC
        • Appropriate monitoring of complete blood counts during ADC therapy; thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias

        MODULE 5: Gastrointestinal (GI) Adverse Events (AEs) Documented with ADCs

        • Rates of various GI issues (eg, nausea, vomiting, diarrhea, constipation, abdominal pain) in patients receiving ADC therapy
        • Indications for prophylactic antiemetics and antidiarrheals for patients who are about to start treatment with an ADC
        • Role of nutritional counselling and diet modifications during ADC treatment
        • Potential advantages of complementary therapies, such as acupuncture and yoga, in managing GI side effects of ADCs

        MODULE 6: Recognition and Management of Interstitial Lung Disease (ILD)/Pneumonitis Associated with ADCs

        • Pathophysiology of ILD/pneumonitis associated with ADCs; baseline risk factors for its development
        • Rates, severity and timing of ILD/pneumonitis in clinical trial experiences with various ADCs
        • Appropriate workup for patients suspected of experiencing therapy-related ILD/pneumonitis; strategies to distinguish drug-related pulmonary toxicity from other potential causes
        • Guidelines for treatment modifications and discontinuation for patients experiencing ILD/pneumonitis; indications for restarting ADC therapy after resolution
        • Utility of other supportive care measures, such as corticosteroids and oxygen supplementation, for patients experiencing ILD/pneumonitis

        MODULE 7: Potential for Mucositis/Stomatitis with ADCs

        • Incidence and severity of mucositis/stomatitis with various approved and investigational ADCs
        • Counseling patients on the importance of oral hygiene during treatment with ADCs known to cause mucositis/stomatitis
        • Role of steroid mouthwash, prophylactic antibiotics/antifungals and pain medications for patients who are at risk for or are experiencing mucositis/stomatitis
        • Dietary recommendations for patients experiencing mucositis/stomatitis

        MODULE 8: Ocular Toxicities with ADCs

        • Pathophysiology of ocular AEs associated with certain ADCs; spectrum, incidence and severity of ocular toxicities with different agents
        • Optimal patient counseling and education regarding signs of ocular toxicity and the importance of early reporting of symptoms
        • Utility of other prophylactic and supportive care measures to mitigate and manage ocular toxicities
        • Importance of interdisciplinary coordination with eye-care professionals in the identification and management of treatment-related ocular AEs

        MODULE 9: Cardiovascular AEs Associated with Select ADCs

        • Pathophysiology of the cardiotoxicity associated with anti-HER2 therapies, including ADCs
        • Incidence of left ventricular dysfunction noted with HER2-targeted ADCs in clinical trial experiences
        • Appropriate monitoring of left ventricular ejection fraction (LVEF) at baseline and during treatment with HER2-targeted ADCs
        • Threshold for treatment interruption for patients experiencing LVEF decrease; indications for restarting HER2-targeted ADC therapy after recovery
        • Role of interdisciplinary coordination with cardiologists when monitoring for and managing cardiac toxicities associated with HER2-targeted ADCs

        MODULE 10: Other Toxicities Reported with 1 or More ADCs

        • Incidence and management of peripheral neuropathy associated with various ADCs
        • Rates of alopecia reported with ADC treatment; available strategies to reduce the incidence/severity of hair loss or limit its psychosocial impact (eg, scalp-cooling methods, wigs/hair pieces)
        • Available strategies to ameliorate the symptoms of rash and other cutaneous reactions associated with ADCs (eg, antihistamines, topical steroids, emollients)
        • Spectrum of other toxicities (eg, fatigue, hemorrhage, effusion/edema, hyperglycemia) associated with 1 or more ADCs used in the treatment of cancer

        Target Audience
        This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

        Learning Objectives
        Upon completion of this activity, participants should be able to

        • Consider the scientific justification for antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the differential targets, structural components and mechanisms of activity of different clinically available and investigational ADCs.
        • Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
        • Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
        • Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs demonstrating efficacy in the management of various tumor types, and educate patients about to commence therapy with these approaches regarding the potential development of adverse events and what to do if they are suspected.
        • Recall strategies commonly employed to identify, manage and mitigate toxicities resulting from anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
        • Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of various ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.

        Accreditation Statement
        Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

        Credit Designation Statements
        This educational activity for 1.5 contact hours is provided by Research To Practice.

        This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

        Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
        The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/ADCs/ILNA.

        ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

        Credit Form
        To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

        Privacy Policy
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        Unlabeled/Unapproved Uses Notice
        There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

        Content Validation and Disclosures
        Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Ms Arn — Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc. Ms Carroll — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Lilly, Novartis. Dr Garon — Consulting Agreements: AbbVie Inc, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, GSK, Hexagon Bio, I-Mab Biopharma, IO Biotech, iTeos Therapeutics, LianBio, Merck, Novartis, Oxford BioTherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Samsung Bioepis, Sanofi, Servier Pharmaceuticals LLC, Strata Oncology, Synthekine, TransCode Therapeutics, Verastem Inc; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics, Nuvalent, Servier Pharmaceuticals LLC. Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

        MODERATOR — Dr Moore — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

        RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
        Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

        Supporters
        This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Merck.

        Location
        San Antonio Marriott Rivercenter
        101 Bowie St
        San Antonio, TX 78205
        Hotel Phone: (210) 223-1000

        Meeting Room
        Grand Ballroom A-F (Third Floor)

        Directions
        The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

         

        Registration is now closed.

        What Is Molecular Residual Disease Analysis and Why Is It Clinically Relevant in Colorectal Cancer?

        Accreditation types: 1 NCPD

        Expires: March 2027

        To play this presentation please log in.

        Don't have an account?

        Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

        Faculty

        Christopher Lieu

        Faculty

        Christopher Lieu

        MD

        University of Colorado Cancer Center Aurora, Colorado

        Professor of Medicine Associate Director for Clinical Research Director, GI Medical Oncology

        TARGET AUDIENCE
        This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal cancer.

        PURPOSE STATEMENT
        By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with colorectal cancer.

        DESIRED LEARNING OUTCOME
        At the conclusion of this activity, the learner will be able to show objective and subjective awareness of the factors affecting patient selection for novel assays and agents in the field of colorectal cancer in order to educate and support patients and their families in decision-making and the patient journey as evidenced by self-reported change in knowledge level in the evaluation provided to learners at the completion of the activity.

        At the end of the activity, learners will also be able to

        • Develop an understanding of the clinical relevance of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in colorectal cancer (CRC).
        • Recognize the scientific rationale for the use of ctDNA to detect molecular residual disease (MRD) in patients with CRC, and provide appropriate patient education.
        • Outline optimal approaches to and timing of ctDNA-based assessment of MRD for patients with CRC.
        • Appreciate available data documenting the clinical utility of ctDNA testing in risk stratification, surveillance and treatment decision-making for patients with CRC.
        • Consider the current and potential role of ctDNA assessment in order to counsel patients with early- and advanced-stage CRC regarding personalized treatment recommendations.

        ACCREDITATION STATEMENT
        Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

        CREDIT DESIGNATION STATEMENT
        This educational activity for 1 contact hour is provided by RTP during the period of March 6, 2026 to March 6, 2027.

        This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

        ONCC/ILNA CERTIFICATION INFORMATION
        The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONU2025/MRDCRC/ILNA.

        ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

        PRIVACY POLICY
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        FOR SUCCESSFUL COMPLETION
        Video Interview: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONU2025/MRDCRC/Video/NCPD.

        CONTENT VALIDATION AND DISCLOSURES
        Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Christopher Lieu, MD
        Professor of Medicine
        Associate Director for Clinical Research
        Director, GI Medical Oncology
        University of Colorado Cancer Center
        Aurora, Colorado

        Dr Lieu has consulting agreements (to institution) with Pfizer Inc and conducts contracted research (all to institution) for Genentech, a member of the Roche Group, Janssen Biotech Inc, Sanofi. All of these relevant financial relationships have been mitigated.

        EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

        RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

        These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

        These activities are supported by an educational grant from Natera Inc.

        Release date: March 6, 2026
        Expiration date: March 6, 2027

        There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

        Bando H et al. A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study. Gastrointestinal Cancers Symposium 2025;Abstract LBA22.

        Kasi PM et al. Patient-reported outcomes from the BESPOKE CRC study. Gastrointestinal Cancers Symposium 2024;Abstract 54.

        Kasi PM et al. BESPOKE study protocol: A multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open 2021;11(9). Abstract

        Kopetz S et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Gastrointestinal Cancers Symposium 2020;Abstract 8.

        Kotani D et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29(1):127-34. Abstract

        Morris VK et al. Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study. Gastrointestinal Cancers Symposium 2024;Abstract 5.

        Naidoo M et al. ctDNA and adjuvant therapy for colorectal cancer: Time to re-invent our treatment paradigm. Cancers (Basel) 2021;13(2):346. Abstract

        Nowak JA et al. Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. Gastrointestinal Cancers Symposium 2025;Abstract LBA14.

        Rolfo C, Russo A. Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol 2020;17(9):523-4. Abstract

        Shah PK et al. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. Gastrointestinal Cancers Symposium 2025;Abstract 15.

        Tie J et al. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG). ASCO 2025;Abstract 3503.

        Tie J et al. Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. ASCO 2022;Abstract LBA100.

        Tie J et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261-72. Abstract

        Yukami H et al. Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN. ASCO 2024;Abstract 6.

        Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma

        Accreditation types: 1.25 NCPD

        Expires: October 2026

        To play this presentation please log in.

        Don't have an account?

        Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

        Faculty

        Beth Faiman

        Beth Faiman

        PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

        Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

        Adult Nurse Practitioner, Department of Hematology and Medical Oncology

        Case Comprehensive Cancer Center, Cleveland, Ohio

        Member, Population and Cancer Prevention Program

        TARGET AUDIENCE
        This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma (MM).

        PURPOSE STATEMENT
        By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with MM. 

        DESIRED LEARNING OUTCOME
        At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with chimeric antigen receptor (CAR) T-cell therapy for MM in order to educate, counsel and assist patients and their families in decision-making.

        At the end of the activity, learners will also be able to

        • Understand the scientific rationale for and mechanism of action of BCMA-directed CAR T-cell therapy in patients with multiple myeloma (MM), and appreciate the similarities and differences among available agents in this class.
        • Understand the clinical research database with BCMA-directed CAR T-cell therapy in the management of relapsed/refractory MM, and counsel patients regarding the risks and benefits of this novel approach.
        • Understand the pathophysiology of cytokine release syndrome and neurologic toxicity associated with CAR T-cell therapy for MM, and develop strategies to optimally identify and manage these side effects.
        • Recognize the spectrum, frequency and severity of other adverse events associated with CAR T-cell therapy for patients with MM, and consider recommended approaches to prevent, ameliorate and manage these toxicities.
        • Review the logistical and practical requirements associated with CAR T-cell therapy for MM in order to provide appropriate education to eligible patients.

        ACCREDITATION STATEMENT
        Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

        CREDIT DESIGNATION STATEMENT
        This educational activity for 1.25 contact hours is provided by RTP during the period of October 2025 to October 2026. 

        This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

        ONCC/ILNA CERTIFICATION INFORMATION
        The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONU25/CARTMM/1/ILNA.

        ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

        PRIVACY POLICY
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        FOR SUCCESSFUL COMPLETION
        This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONU25/CARTMM/1/Video/NCPD.

        CONTENT VALIDATION AND DISCLOSURES
        Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
        Adult Nurse Practitioner
        Department of Hematology and Medical Oncology
        Cleveland Clinic Taussig Cancer Institute
        Member, Population and Cancer Prevention Program
        Case Comprehensive Cancer Center
        Cleveland, Ohio

        Dr Faiman is on advisory committees and has consulting agreements with Janssen Biotech Inc and Sanofi.  All of these relevant financial relationships have been mitigated.

        EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME and NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company. 

        RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

        These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

        These activities are supported by an educational grant from Johnson & Johnson.

        Release date: October 2025
        Expiration date: October 2026

        There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

        Bellerive C et al. Optimizing transitions of care in multiple myeloma immunotherapy: Nurse roles. Clin J Onc Nurs 2025;29(1):E7-16. Abstract

        Bishop MR, Kay GE. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists. Semin Oncol 2024;51(3-4):87-94. Abstract

        Catamero D et al. Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma. Semin Oncol Nurs 2024;40(5):151712. Abstract

        Crombie JL et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 2024;143(16):1565-75. Abstract

        Dreyling M et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood 2024;143(17):1713-25. Abstract

        Neelapu SS et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 2024;143(6):496-506. Abstract

        Oluwole OO et al. Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3. ASCO 2024;Abstract 6531.

        Roddie C et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med 2024;391(23):2219-30. Abstract

        Shahid Z et al. Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther 2024;30(10):955-69. Abstract

        Consensus or Controversy?: Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Follicular Lymphoma

        Accreditation types: 1.25 ABIM MOC, ABS MOC, ACPE, CME / 1.25 NCPD

        Expires: October 2026

        To play this presentation please log in.

        Don't have an account?

        Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

        Access CME evaluation
        Access NCPD evaluation
        Access ACPE evaluation

        Faculty

        Jennifer Crombie

        Faculty

        Jennifer Crombie

        MD

        Dana-Farber Cancer Institute, Boston, Massachusetts

        Assistant Professor of Medicine, Harvard Medical School

        Laurie H Sehn

        Faculty

        Laurie H Sehn

        MD, MPH

        BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada

        Chair, Lymphoma Tumour Group

        University of British Columbia, Vancouver, British Columbia, Canada

        Clinical Professor of Medicine, Division of Medical Oncology

        Vancouver, British Columbia, Canada

        Podcast Editor, Blood

        Jeremy S Abramson

        Moderator

        Jeremy S Abramson

        MD, MMSc

        Massachusetts General Hospital, Boston, Massachusetts

        Director, Center for Lymphoma

        Harvard Medical School, Boston, Massachusetts

        Professor of Medicine

        TARGET AUDIENCE
        This program is intended for hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of follicular lymphoma (FL).

        PURPOSE STATEMENT
        By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with follicular lymphoma.

        LEARNING OBJECTIVES

        • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) FL.
        • Develop an understanding of available clinical trial findings supporting the use of bispecific antibodies targeting CD20 and CD3 for the management of R/R FL.
        • Identify patients with R/R FL who may be candidates for chimeric antigen receptor T-cell therapy directed at CD19.
        • Assess recently presented clinical research findings with the use of CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in the care of patients with R/R FL.
        • Evaluate published clinical research findings establishing the efficacy and safety of combined Bruton tyrosine kinase inhibitor/anti-CD20 antibody therapy for patients with R/R FL.
        • Consider recommended approaches to prevent, ameliorate and manage toxicities associated with various therapies commonly used in the care of patients with R/R FL.
        • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

        ACCREDITATION, SUPPORT AND CREDIT STATEMENT
        In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

        PHYSICIAN CREDIT DESIGNATION STATEMENT
        Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
        Successful completion of this CME activity, which includes participation in the evaluation components, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

        Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS). For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

        Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

        NURSING CONTINUING PROFESSIONAL DEVELOPMENT
        Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours and 1.25 contact hours in the area of pharmacology.

        ONCC/ILNA CERTIFICATION INFORMATION
        The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/SOHO2025/FollicularLymphoma/Sep5/ILNA.

        ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

        CONTINUING PHARMACY EDUCATION
        Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
        Universal Activity Number: JA0007322-0000-25-048-H01-P

        For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the National Association of Boards of Pharmacy (NABP) only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy

        PRIVACY POLICY
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        HOW TO USE THIS CE ACTIVITY
        To receive credit for an activity in this series, the participant should review the CME, NCPD or ACPE information, listen to or view the recording, review the downloadable slide set, complete the post-test with a score of 80% or better (CME and NCPD only) and fill out the evaluation. Evaluation location URLs are noted below:
        CME Evaluations: ResearchToPractice.com/SOHO2025/FL/Video/CME (video)
        NCPD Evaluations: ResearchToPractice.com/SOHO2025/FL/NCPD/Video (video)
        ACPE Evaluations: ResearchToPractice.com/SOHO2025/FL/ACPE/Video (video)

        DISCLOSURE & FINANCIAL RELATIONSHIPS POLICY
        Medical Learning Institute Inc (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Jennifer Crombie, MD
        Assistant Professor of Medicine
        Harvard Medical School
        Dana-Farber Cancer Institute
        Boston, Massachusetts

        Advisory Committees: Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Lilly, Novartis, Regeneron Pharmaceuticals Inc.

        Laurie H Sehn, MD, MPH
        Chair, Lymphoma Tumour Group
        BC Cancer Centre for Lymphoid Cancer
        Clinical Professor of Medicine
        Division of Medical Oncology
        University of British Columbia
        Podcast Editor, Blood
        Vancouver, British Columbia, Canada

        Consulting/Honoraria: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, CARGO Therapeutics, Chugai Pharmaceutical Co Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: CARGO Therapeutics.

        SURVEY PARTICIPANTS — John N Allan, MD — Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeOne. Ann LaCasce, MD, MMSc — Advisory Committees: Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Pierre Fabre, Takeda Pharmaceuticals USA Inc. Loretta J Nastoupil, MD — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Genentech, a member of the Roche Group; Contracted Research: BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genentech, a member of the Roche Group.

        MODERATOR
        Jeremy S Abramson, MD, MMSc
        Director, Center for Lymphoma
        Massachusetts General Hospital
        Professor of Medicine
        Harvard Medical School
        Boston, Massachusetts

        Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

        PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.

        This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

        Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

        This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, Novartis, and Regeneron Pharmaceuticals Inc.

        Release date: October 10, 2025
        Expiration date: October 10, 2026

        After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

        Dr Crombie

        Brem E et al. Odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma (FL): Results of the safety lead-in of the phase 3 Olympia-1 study. ASH 2024;Abstract 4411.

        Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract

        Budde LE et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study. ASH 2021;Abstract 127.

        Falchi L et al. Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the Epcore NHL-2 trial. ASH 2024;Abstract 342.

        Falchi L et al. Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the Mithic-FL1 trial. ASH 2024;Abstract 340.

        Falchi L et al. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities. Blood 2023;141(5):467-80. Abstract

        Falchi L et al. EPCORE FL-1: Phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R2) vs R2 alone in patients with relapsed or refractory follicular lymphoma. ASH 2023;Abstract 3053.

        Ghosh N et al. SWOG 2308: Randomized phase III study of mosunetuzumab versus rituximab for low–tumor burden follicular lymphoma. JCO Oncol Adv 2025;2(1):e2500037. Abstract

        Kim TM et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol 2024;35(11):1039-47. Abstract

        Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract

        Linton KM et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: First data disclosure from the Epcore NHL-1 follicular lymphoma dose-expansion cohort. ASH 2023;Abstract 1655.

        Nastoupil L et al. CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma. EHA 2022;Abstract P1125.

        Sehn LH et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood 2025;145(7):708-19. Abstract

        Villasboas JC et al. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with extended follow-up. ASH 2023;Abstract 3041.

        Vitolo U et al. Trial in progress: Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma and marginal zone lymphoma (OLYMPIA-5). EHA 2023;Abstract PB2266.

        Dr Abramson

        Ahmed S et al. Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): Impact of prior lines of therapy, bendamustine exposure, and disease progression ≤ 24 months of initial systemic therapy. ICML 2025;Abstract 142.

        Bartlett NL et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study. ASH 2022;Abstract 610.

        Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract

        Dreyling M et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood 2024;143(17):1713-25. Abstract

        Dreyling M et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL network. ASH 2022;Abstract.

        Fowler NH et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nat Med 2022;28(2):325-32. Abstract

        Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91-103. Abstract

        Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract

        Morschhauser F et al. Lisocabtagene maraleucel in follicular lymphoma: The phase 2 TRANSCEND FL study. Nat Med 2024;30(8):2199-207. Abstract

        Nastoupil L et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Transcend FL 2-year follow-up. ASH 2024;Abstract 4387.

        Neelapu SS et al. 5-year follow-up analysis from ZUMA-5: A phase 2 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2024;Abstract 864.

        Neelapu SS et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 2024;143(6):496-506. Abstract

        Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2021;Abstract 93.

        Shadman M et al. Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study. ASH 2024;Abstract 4407.

        Taszner M et al. Primary analysis of the phase 2 ELM-2 study: Odronextamab in patients with relapsed/refractory follicular lymphoma. EHA 2024;Abstract S232.

        Thieblemont C et al. Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 ELARA 4-year update. ASH 2024;Abstract 3034.

        Thieblemont C et al. Three-factor prediction model for grade 2+ cytokine release syndrome in large B-cell lymphoma patients receiving epcoritamab monotherapy. ASH 2024;Abstract 4491.

        Dr Sehn

        Alderuccio JP et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12(1):e23-34. Abstract

        Alderuccio JP et al. Loncastuximab tesirine with rituximab induces robust and durable complete metabolic responses in high-risk relapsed/refractory follicular lymphoma. ASH 2024;Abstract 337.

        Chavez JC et al. A randomized phase II study of mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). ASH 2024;Abstract 989.

        Chavez JC et al. 3-year analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). ASH 2023;Abstract 894.

        Cheson BD et al. Diffuse large B-cell lymphoma: New targets and novel therapies. Blood Cancer J 2021;11(4):68. Abstract

        Cordoba R et al. Golcadomide (GOLCA), a cereblon E3 ligase modulator (CELMOD™) agent ± rituximab (R), in patients (PTS) with relapsed/refractory follicular lymphoma (R/R FL): Updated phase 1/2 study results. EHA 2025;Abstract PS1879.

        Gopal AK et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study. J Clin Oncol 2018;36(23):2405-12. Abstract

        Jurczak W et al. Nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma: Results from the phase 2 Bellwave-003 study. ASH 2024;Abstract 1634.

        Østenstad B et al. SAKK 35/14 randomized trial of rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. Hematol Oncol 2023;41(S2):117-9. Abstract

        Reinke S et al. CD19 expression is retained in patients with relapsed/refractory follicular or marginal zone lymphoma after receiving tafasitamab, lenalidomide, and rituximab in the inMIND study. EHA 2025;Abstract PF1006.

        Sehn LH et al. Post hoc analysis of outcomes by POD24 status from the inMIND study of tafasitamab plus lenalidomide and rituximab in relapsed or refractory follicular lymphoma. ICML 2025;Abstract 234.

        Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.

        Sehn L et al. MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma. Hematol Oncol 2023;41(S2):168-70. Abstract

        Trotman J et al. Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study. EHA 2023;Abstract P1080.

        Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2023;41(33):5107-17. Abstract

        • SOHO 2025

        Consensus or Controversy?: Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma

        Accreditation types: 1.25 ABIM MOC, ACPE / 1.25 NCPD

        Expires: October 2026

        To play this presentation please log in.

        Don't have an account?

        Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

        Access CME evaluation
        Access NCPD evaluation
        Access ACPE evaluation

        Faculty

        Meletios-Athanasios (Thanos) C Dimopoulos

        Faculty

        Meletios-Athanasios (Thanos) C Dimopoulos

        MD

        National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece

        Professor and Chairman, Plasma Cell Dyscrasias Unit, Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine

        Hans Lee

        Faculty

        Hans Lee

        MD

        Sarah Cannon Research Institute, Nashville, Tennessee

        Director, Multiple Myeloma Research

        Noopur Raje

        Faculty

        Noopur Raje

        MD

        Massachusetts General Hospital Cancer Center, Boston, Massachusetts

        Director, Center for Multiple Myeloma, Rita Kelley Chair in Oncology

        Harvard Medical School Boston, Massachusetts

        Professor of Medicine

        Joseph Mikhael

        Moderator

        Joseph Mikhael

        MD, MEd

        City of Hope Cancer Center, Phoenix, Arizona

        Professor, Clinical Genomics and Therapeutics, Translational Genomics Research Institute (TGen)

        International Myeloma Foundation, Phoenix, Arizona

        Chief Medical Officer

        TARGET AUDIENCE
        This program is intended for hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of multiple myeloma (MM).

        PURPOSE STATEMENT
        By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with multiple myeloma.

        LEARNING OBJECTIVES

        • Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) MM.
        • Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered or recommended.
        • Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
        • Recall recently presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
        • Analyze the mechanism of action of, published efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators, and use this information to prepare for the potential clinical availability of these agents for patients with R/R MM.
        • Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly administered to patients with R/R MM.

        ACCREDITATION, SUPPORT AND CREDIT STATEMENT
        In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


        PHYSICIAN CREDIT DESIGNATION STATEMENT
        Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
        Successful completion of this CME activity which includes participation in the evaluation components, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

        Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS). For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

        Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

        NURSING CONTINUING PROFESSIONAL DEVELOPMENT
        Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours and 1.25 contact hours in the area of pharmacology.

        ONCC/ILNA CERTIFICATION INFORMATION
        The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/SOHO2025/Relapsed-RefractoryMM/Sep4/ILNA.

        ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

        CONTINUING PHARMACY EDUCATION
        Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
        Universal Activity Number: JA0007322-0000-25-046-H01-P

        For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the National Association of Boards of Pharmacy (NABP) only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy

        PRIVACY POLICY
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        HOW TO USE THIS CE ACTIVITY
        To receive credit for an activity in this series, the participant should review the CME, NCPD or ACPE information, listen to or view the recording, review the downloadable slide set, complete the post-test with a score of 80% or better (CME and NCPD only) and fill out the evaluation. Evaluation location URLs are noted below:
        CME Evaluations: ResearchToPractice.com/SOHO2025/RRMM/CME (audio), ResearchToPractice.com/SOHO2025/RRMM/Video/CME (video)
        NCPD Evaluations: ResearchToPractice.com/SOHO2025/RRMM/NCPD (audio), ResearchToPractice.com/SOHO2025/RRMM/NCPD/Video (video)
        ACPE Evaluations: ResearchToPractice.com/SOHO2025/RRMM/ACPE (audio), ResearchToPractice.com/SOHO2025/RRMM/ACPE/Video (video)

        DISCLOSURE & FINANCIAL RELATIONSHIPS POLICY
        Medical Learning Institute Inc (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Meletios-Athanasios (Thanos) C Dimopoulos, MD
        Professor and Chairman
        Plasma Cell Dyscrasias Unit
        Section of Hematology and Medical Oncology
        Department of Clinical Therapeutics
        School of Medicine
        National and Kapodistrian University of Athens
        Alexandra Hospital
        Athens, Greece

        Advisory Committees, Consulting Agreements and Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma SA, Takeda Pharmaceutical Company Limited.

        Hans Lee, MD
        Director, Multiple Myeloma Research
        Sarah Cannon Research Institute
        Nashville, Tennessee

        Consulting Agreements: Alexion Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Alexion Pharmaceuticals, Amgen Inc, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc.

        Noopur Raje, MD
        Director, Center for Multiple Myeloma
        Rita Kelley Chair in Oncology
        Massachusetts General Hospital Cancer Center
        Professor of Medicine
        Harvard Medical School
        Boston, Massachusetts

        Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi.

        SURVEY PARTICIPANTS — Natalie S Callander, MD, has no relevant financial relationships to disclose. Thomas Martin, MD — Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson, Sanofi; Data and Safety Monitoring Boards/Committees: Lilly. Surbhi Sidana, MD — Advisory Committees and Consulting Agreements: AbbVie Inc, Arcellx, BioLineRx, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol Myers Squibb, Janssen Biotech Inc, Magenta Therapeutics, Novartis; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb.

        MODERATOR
        Joseph Mikhael, MD, MEd
        Professor, Clinical Genomics and Therapeutics
        Translational Genomics Research Institute (TGen)
        City of Hope Cancer Center
        Chief Medical Officer
        International Myeloma Foundation
        Phoenix, Arizona

        Consulting Agreements: Bristol Myers Squibb, Janssen Biotech Inc, Menarini Group, Sanofi.

        PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.

        This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

        Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

        This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

        Release date: October 2, 2025
        Expiration date: October 2, 2026

        After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

        Dr Raje

        Agha ME et al. CARTITUDE-2 cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. EHA 2022;Abstract S185.

        Bal S et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM). ASH 2024;Abstract 922.

        Freeman CL et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. ASH 2024;Abstract 1031.

        Frigault MJ et al. Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed and/or refractory multiple myeloma: Results from at least 1-year follow-up in all patients. ASH 2023;Abstract 1023.

        Hillengass J et al. Ciltacabtagene autoleucel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 biological correlative analyses and updated clinical data. EHA 2022;Abstract P959.

        Mateos M-V et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. International Myeloma Society 2024;Abstract OA-65.

        Rodriguez-Otero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388(11):1002-14. Abstract

        San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335-47. Abstract

        Usmani S et al. KarMMa-2 cohort 2a: Efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. ASH 2022;Abstract 361.

        Voorhees PM et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2025;Abstract 7507.

        Dr Lee

        Bahlis NJ et al. Talquetamab (tal) + daratumumab (dara) + pomalidomide (pom) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the phase 1b TRIMM-2 study. International Myeloma Society (IMS) 2024;Abstract OA-01.

        Baljevic M et al. Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2025;Abstract 7527.

        Banerjee R et al. IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels. Blood Adv 2025;[Online ahead of print]. Abstract

        Bumma N et al. Linvoseltamab for treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2024;42(22):2702-12. Abstract

        Chari A et al. Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk 2024;24(10):665-93. Abstract

        Chari A et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Phase 1/2 results from MonumenTAL-1. Blood 2022;140(Suppl 1):384-7. Abstract

        Chari A et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387(24):2232-44. Abstract

        Cohen YC et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2025;392(2):138-49. Abstract

        Cohen Y et al. Talquetamab (tal) + teclistamab (tec) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated phase 1B results from RedirecTT-1 with >1 year of follow-up. IMS 2024;Abstract OA-03.

        Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.

        Kowalski A et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Adv 2025;[Online ahead of print]. Abstract

        Kowalski A et al. Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, elranatamab or talquetamab. ASH 2024;Abstract 932.

        Lesokhin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29(9):2259-67. Abstract

        Narayan N et al. Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma. JAAD Case Rep 2022;31:66-8. Abstract

        Raab MS et al. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) trial. ASH 2024;Abstract 493.

        Reese M et al. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol 2024;15:1424925. Abstract

        Richter J et al. Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. ASH 2024;Abstract 1021.

        Rifkin R et al. Optec: A phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM): Updated results. ASH 2024;Abstract 4753.

        Rodriguez-Otero P et al. GPRC5D as a novel target for the treatment of multiple myeloma: A narrative review. Blood Cancer J 2024;14(1):24. Abstract

        Tomasson M et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM). ASH 2023;Abstract 3385.

        Prof Dimopoulos

        Bjorklund CC et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 2020;34(4):1197-1201. Abstract

        Charliński G et al. Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma. Cancers (Basel) 2021;13(18):4666. Abstract

        Dimopoulos MA et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 2025;22(9):680-700. Abstract

        Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391(5):408-21. Abstract

        Dimopoulos MA et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract LB3440.

        Gay F et al. Iberdomide maintenance after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. EHA 2024:Abstract P958.

        Hartley-Brown MA et al. Mezigdomide — A novel cereblon E3 ligase modulator under investigation in relapsed/refractory multiple myeloma. Cancers (Basel) 2024;16(6):1166. Abstract

        Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(5):393-407. Abstract

        Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.

        Hungria VTM et al. Characterization and management of ocular events in patients (Pts) treated with belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) in the DREAMM-7 study. International Myeloma Society (IMS) 2024;Abstract P-396.

        Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Int J Hematol 2016;104(3):293-9. Abstract

        Liu Y et al. Targeting Ikaros and Aiolos: Reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol 2024;17(8):445-65. Abstract

        Lonial S et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol 2022;9(11):e822-32. Abstract

        Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM). EHA 2021;Abstract S187.

        Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the dose-expansion phase of the CC-220-MM-001 trial. Blood 2021;138(Suppl 1):162. Abstract

        Mateos M-V et al. Results from DREAMM-7 a randomized phase 3 study of belantamab mafodotin + bortezomib, and dexamethasone vs daratumumab + bortezomib, and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract S214.

        Offidani M et al. Belantamab mafodotin for the treatment of multiple myeloma: An overview of the clinical efficacy and safety. Drug Des Devel Ther 2021;15:2401-15. Abstract

        Quach H et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. IMS 2024;Abstract P-413.

        Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract

        Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.

        Terpos E et al. Practical guidance on clinical management of belantamab mafodotin-associated ocular events. Am J Hematol 2025;100(10):1839-50. Abstract

        Trudel S et al. Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial. ASCO 2025;Abstract 7515.

        Trudel S et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract LBA105.

        van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: First results of the phase 2 EMN26 study. ASH 2023;Abstract 208.

        • SOHO 2025

        An Interview with Xavier Leleu, MD, PhD — Optimizing the Care of Patients with Newly Diagnosed Multiple Myeloma

        Accreditation types: 1.25 NCPD

        Expires: August 2026

        To play this presentation please log in.

        Don't have an account?

        Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

        Faculty

        Xavier Leleu

        Xavier Leleu

        MD, PhD

        Hôpital La Miletrie, Poitiers University Hospital, Poitiers, France

        Professor, Head of Myeloma Clinic, Head of Department of Hematology

        Related program:
        Oncology Nursing Update: An Interview with Charise Gleason, MSN, NP-C, AOCNP — Optimizing the Care of Patients with Newly Diagnosed Multiple Myeloma

        TARGET AUDIENCE
        This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

        PURPOSE STATEMENT
        By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with multiple myeloma.

        LEARNING OBJECTIVES

        • Understand how age, comorbidities, cytogenetic profile and fitness for stem cell transplantation influence the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM).
        • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for MM in patients eligible for stem cell transplant in order to effectively educate individuals about personalized treatment recommendations.
        • Evaluate published and recently presented research findings with CD38-based regimens as front-line treatment for MM in patients deemed ineligible for stem cell transplant, and identify individuals for whom a quadruplet regimen would be appropriate.
        • Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used front-line regimens for MM.

        ACCREDITATION STATEMENT
        Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

        CREDIT DESIGNATION STATEMENT
        Video Program: This educational activity for 1.25 contact hours is provided by RTP during the period of August 2025 to August 2026.

        This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

        ONCC/ILNA CERTIFICATION INFORMATION
        The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONU25/MM/1/ILNA.

        ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

        PRIVACY POLICY
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        FOR SUCCESSFUL COMPLETION
        Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONU25/MM/1/Video/NCPD.

        CONTENT VALIDATION AND DISCLOSURES
        Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess financial relationships with faculty, planners and managers of NCPD activities. Financial relationships are identified and resolved through a financial relationship resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Xavier Leleu, MD, PhD
        Professor, Head of Myeloma Clinic
        Head of Department of Hematology
        Hôpital La Miletrie
        Poitiers University Hospital
        Poitiers, France

        Advisory Committees, Consulting Agreements and Data and Safety Monitoring Boards/Committees: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, GSK, Ichnos Glenmark Innovation, Janssen Biotech Inc, Kite, A Gilead Company, Novartis, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Takeda Pharmaceuticals USA Inc.

        EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

        RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

        These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

        These activities are supported by an educational grant from Sanofi.

        Release date: August 2025
        Expiration date: August 2026

        There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

        Kumar SK et al. NCCN Guidelines® Insights: Multiple Myeloma, version 2.2025. J Natl Compr Canc Netw 2025;23(5):132-40. Abstract

        Lancman G et al. Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2021;21:e470-6. Abstract

        Miceli TS et al. Supportive care in multiple myeloma: Current practices and advances. Cancer Treat Res Commun 2021;29:100476. Abstract

        Moore KLF et al. Improved survival in myeloma patients–A nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden. Clin Lymphoma Myeloma Leuk 2021;108(6):21. Abstract

        An Interview with Charise Gleason, MSN, NP-C, AOCNP — Optimizing the Care of Patients with Newly Diagnosed Multiple Myeloma

        Accreditation types: 1.25 NCPD

        Expires: July 2026

        To play this presentation please log in.

        Don't have an account?

        Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

        Faculty

        Charise Gleason

        Charise Gleason

        MSN, NP-C, AOCNP

        Emory Healthcare Atlanta, Georgia

        VP and Chief APP Officer

        Related program:
        Oncology Nursing Update: An Interview with Xavier Leleu, MD, PhD — Optimizing the Care of Patients with Newly Diagnosed Multiple Myeloma

        TARGET AUDIENCE
        This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

        PURPOSE STATEMENT
        By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with multiple myeloma.

        LEARNING OBJECTIVES

        • Understand how age, comorbidities, cytogenetic profile and fitness for stem cell transplantation influence the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM).
        • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for MM in patients eligible for stem cell transplant in order to effectively educate individuals about personalized treatment recommendations.
        • Evaluate published and recently presented research findings with CD38-based regimens as front-line treatment for MM in patients deemed ineligible for stem cell transplant, and identify individuals for whom a quadruplet regimen would be appropriate.
        • Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used front-line regimens for MM.

        ACCREDITATION STATEMENT
        Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

        CREDIT DESIGNATION STATEMENT
        This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

        Video Program: This educational activity for 1.25 contact hours is provided by RTP during the period of July 2025 to July 2026.

        This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

        ONCC/ILNA CERTIFICATION INFORMATION
        The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONU2025/NewlyDiagnosedMM/ILNA.

        ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

        PRIVACY POLICY
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        FOR SUCCESSFUL COMPLETION
        Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONU25/MM/Video/NCPD.


        CONTENT VALIDATION AND DISCLOSURES
        Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Charise Gleason, MSN, NP-C, AOCNP
        VP and Chief APP Officer
        Emory Healthcare
        Atlanta, Georgia

        No relevant financial relationships to disclose.

        EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

        RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

        These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

        These activities are supported by an educational grant from Sanofi.

        Release date: July 2025
        Expiration date: July 2026

        There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

        Kumar SK et al. NCCN Guidelines® Insights: Multiple Myeloma, version 2.2025. J Natl Compr Canc Netw 2025;23(5):132-40. Abstract

        Lancman G et al. Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2021;21:e470-6. Abstract

        Miceli TS et al. Supportive care in multiple myeloma: Current practices and advances. Cancer Treat Res Commun 2021;29:100476. Abstract

        Moore KLF et al. Improved survival in myeloma patients–A nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden. Clin Lymphoma Myeloma Leuk 2021;108(6):21. Abstract

        Understanding the Current Paradigm and New Approaches in the Care of Patients with Prostate Cancer

        Accreditation types: 1.75 NCPD

        To play this presentation please log in.

        Don't have an account?

        Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

        Faculty

        Rahul Aggarwal

        Faculty

        Rahul Aggarwal

        MD

        University of California, San Francisco

        Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research, Director, Genitourinary Medical Oncology

        UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

        Department of Medicine, Division of Hematology/Oncology, Associate Director for Clinical Research

        Monica Averia

        Faculty

        Monica Averia

        MSN, AOCNP, NP-C

        USC Norris Cancer Center, Los Angeles, California

        Oncology Nurse Practitioner, Clinical Instructor of Medicine

        Kathleen D Burns

        Faculty

        Kathleen D Burns

        RN, MSN, AGACNP-BC, OCN

        City of Hope Comprehensive Cancer Center, Duarte, California

        Genitourinary Medical Oncology

        William K Oh

        Faculty

        William K Oh

        MD

        Yale Cancer Center, New Haven, Connecticut

        Director of Precision Medicine

        Yale School of Medicine, New Haven, Connecticut

        Professor of Medicine, Division of Medical Oncology

        Smilow Cancer Hospital at Greenwich Hospital, New Haven, Connecticut

        Medical Director, Service Line

        TARGET AUDIENCE
        This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

        PURPOSE STATEMENT
        By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with prostate cancer.

        LEARNING OBJECTIVES

        • Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, including for patients with biochemical recurrence after local therapy, and apply this information in the discussion of nonresearch treatment options.
        • Review available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and recognize how these approaches are being integrated into clinical management algorithms.
        • Understand how age, comorbidities, prior therapeutic exposure and other clinical and biological factors affect the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC).
        • Assess the available research supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and identify appropriate candidates for available agents and regimens.
        • Appreciate Phase III data documenting the efficacy of PSMA-targeted radioligand therapy for PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.
        • Implement a plan of care to recognize and manage side effects and toxicities associated with approved therapies for prostate cancer.
        • Recall the design of ongoing clinical trials evaluating other novel therapies for prostate cancer, and counsel appropriate patients about availability and participation.

        ACCREDITATION STATEMENT
        Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

        CREDIT DESIGNATION STATEMENT
        NCPD credit is no longer available for this issue.

        ONCC/ILNA CERTIFICATION INFORMATION
        NCPD credit is no longer available for this issue.

        PRIVACY POLICY
        Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

        FOR SUCCESSFUL COMPLETION
        NCPD credit is no longer available for this issue.

        CONTENT VALIDATION AND DISCLOSURES
        Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

        FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

        Rahul Aggarwal, MD
        Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
        Director, Genitourinary Medical Oncology
        University of California, San Francisco
        Department of Medicine
        Division of Hematology/Oncology
        Associate Director for Clinical Research
        UCSF Helen Diller Family Comprehensive Cancer Center
        San Francisco, California

        Advisory Committees: Novartis; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, FibroGen Inc, Flare Therapeutics, Johnson & Johnson Pharmaceuticals, Merck, ORIC Pharmaceuticals, Pfizer Inc, Xencor; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Merck; Nonrelevant Financial Relationships: Prostate Cancer Clinical Trials Consortium.

        Monica Averia, MSN, AOCNP, NP-C
        Oncology Nurse Practitioner
        Clinical Instructor of Medicine
        USC Norris Cancer Center
        Los Angeles, California

        No relevant financial relationships to disclose.

        Kathleen D Burns, RN, MSN, AGACNP-BC, OCN
        Genitourinary Medical Oncology
        City of Hope Comprehensive Cancer Center
        Duarte, California

        Advisory Committees: Eisai Inc, Janssen Biotech Inc, Sumitomo Dainippon Pharma Oncology Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Pfizer Inc, Sumitomo Dainippon Pharma Oncology Inc.

        William K Oh, MD
        Director of Precision Medicine
        Yale Cancer Center
        Professor of Medicine, Division of Medical Oncology
        Yale School of Medicine
        Medical Director, Service Line
        Smilow Cancer Hospital at Greenwich Hospital
        New Haven, Connecticut

        Advisory Committees: Pfizer Inc; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Cytogen Corporation, Nature’s Toolbox Inc, Novartis, Sumitomo Dainippon Pharma Oncology Inc; Stock Options — Private Companies: Nature’s Toolbox Inc; Stock Options/Stock —Public Companies: GeneDx.

        MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

        RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

        These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

        These activities are supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Novartis.

        Release date: May 2025
        Expiration date: May 2026

        There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

        Dr Aggarwal

        Module 1: Recent Advances in the Treatment of Nonmetastatic Prostate Cancer

        Chi KN et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Genitourinary Cancers Symposium 2022;Abstract 12.

        Freedland SJ et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2023;389(16):1453-65. Abstract

        Freedland SJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. Abstract

        Scher HI et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008;26(7):1148-59. Abstract

         

        Module 4: Current and Future Role of Radiopharmaceuticals in mCRPC

        Gillessen S et al. A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. ESMO 2024;Abstract LBA1.

        Morris MJ et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). ASCO 2021;Abstract LBA4.

        Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23. Abstract

        Sartor O et al. Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). ESMO 2023;Abstract LBA13.

         

        Dr Oh

        Module 2: Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer

        Armstrong AJ et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40(15):1616-22. Abstract

        Chi KN et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13-24. Abstract

        Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract

        Fizazi K et al.  Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686-700. Abstract

        Hussain H et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review. JAMA Oncol 2024;10(6):807-20. Abstract

        Saad F et al. Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial. ESMO 2024;Abstract LBA68.

        Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract

         

        Module 3: Current Role of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

        Agarwal N et al. Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. Genitourinary Cancers Symposium 2025;Abstract LBA18.

        Agarwal N et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial. Lancet 2023;402(10398):291-303. Abstract

        Agarwal N et al. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer 2023;192:113249. Abstract

        Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1(9). Abstract

        de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382(22):2091-102. Abstract

        Efstathiou E et al. Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE. Genitourinary Cancers Symposium 2023;Abstract 170.

        Pritchard CC et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375(5):443-53. Abstract

        Robinson D et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28. Abstract

         

        Ms Burns

        Module 4: Current and Future Role of Radiopharmaceuticals in mCRPC

        Calais J et al. Best patient care practices for administering PSMA-targeted radiopharmaceutical therapy. J Nucl Med 2024;65(11):1666-71. Abstract

        • for-nurses